Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

hardis s.p.a. - albumina - albumina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

crucell italy s.r.l. - albumina - albumina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

alfa wassermann s.p.a. - albumina - albumina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

grifols italia s.p.a. - albumina - albumina

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dudler pharma sàrl - albuminum humanum - soluzione versare perfusione - albuminum humanum 200 g, natrii chloridum, natrii caprylas, n-acetyltryptophanum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml, natrium 123.5 - 136.5 mmol. - rétablissement et maintien du volume sanguin lorsqu’une hypovolémie a été observée et que l’administration d’un colloïde est recommandée. - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

dudler pharma sàrl - albuminum humanum - soluzione versare perfusione - albuminum humanum 250 g, natrii chloridum, natrii caprylas, n-acetyltryptophanum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml, natrium 123.5 - 136.5 mmol. - rétablissement et maintien du volume sanguin lorsqu’une hypovolémie a été observée et que l’administration d’un colloïde est recommandée. - emoderivati

Unione Europea - italiano - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - agenti antineoplastici - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agenti antineoplastici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

csl behring ag - albuminum humanum - soluzione per infusione - albuminum humanum 50 g, n-acetyl-l-tryptophanum natricum, natrii caprylas, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. - recupero e conservazione del kreislaufvolumens, se un volumendefizit è stata identificata, e l'utilizzo di un kolloidsangezeigt è - emoderivati